Shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) saw an uptick in trading volume on Monday . 98,620 shares were traded during mid-day trading, an increase of 35% from the previous session’s volume of 73,062 shares.The stock last traded at $3.87 and had previously closed at $3.68.

The firm has a 50 day moving average price of $3.98 and a 200 day moving average price of $3.99. The firm’s market cap is $124.57 million.

An institutional investor recently bought a new position in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. purchased a new position in shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned about 6.09% of VBI Vaccines, Inc. – at the end of the most recent reporting period.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.